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Abstract
MTC is a rare neuroendocrine thyroid tumour accounting for 3% to 10% of all thyroid malignancies. It can
occur in a sporadic and a hereditary clinical setting. Hereditary MTC may either occur alone (familial MTC,
FMTC) or as part of multiple endocrine neoplasia (MEN) type 2A, or MEN 2B. These disorders are due to
germline mutations in the RET (REarranged during Transfection) gene. In carriers of MEN 2B-associated
RET mutations, prophylactic thyroidectomy is indicated before the first year of life. In the case of MEN 2A-
associated germline RET mutations with a high-risk profile, total thyroidectomy is warranted before the age
of 2 years and certainly before the age of 4 years. At that age the risk of invasive MTC and metastases is
acceptably low. Depending on the type of RET mutation, thyroidectomy can take place at an older age in
patients with a lower risk profile. In case of elevated basal or stimulated serum calcitonin, preventive surgery
including total thyroidectomy and central compartment dissection should be performed regardless of age.
When MTC presents as a palpable tumour, total thyroidectomy should be combined with extensive lymph
node dissection of levels II-V on both sides and level VI to prevent locoregional recurrences.
Introduction
In 1959, Hazard et al. described a case of thyroid
carcinoma with a solid, non-follicular structure with
amyloid in the stroma [1]. This tumour was called
solid or medullary thyroid carcinoma. Since then,
medullary thyroid cancer (MTC) has been regarded
as a separate clinical and pathological entity that
should be distinguished from differentiated thyroid
carcinomas.
MTC is a tumour originating in the parafollicular
C-cells. The parafollicular C-cells are dispersed
inside the follicles of the thyroid gland between the
basal layer and the follicular cells and produce a
hormone called calcitonin. C-cells derive from the
neural crest and are not related to the follicular cells.
They account for about 1% of thyroid cells and are
most numerous at the junction of the upper third and
the lower two-thirds of the thyroid lobes.
MTC is a very rare neuroendocrine thyroid
tumour accounting for 3% to 10% of all thyroid
malignancies [2-4]. It can occur in a sporadic and
a hereditary clinical setting. Hereditary MTC may
either occur alone (familial MTC, FMTC) or as part
of multiple endocrine neoplasia (MEN) type 2A, or
MEN 2B. These disorders are due to germline
mutations in the RET (REarranged during
Transfection) gene [5-7].
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Histopathology 
Macroscopically, MTC is typically located in the
upper two-thirds of the thyroid lobes. Usually it is solid
in consistency and whitish or red in colour.
Histologically, MTC consists of nests of predominantly
round cells with abundant, finely granular amphophilic
cytoplasm and ovoid to round nuclei. Occasional red
cytoplasmic granules are seen, and the supporting
stroma frequently stains for amyloid (these are in fact
calcitonin deposits [8]). In practically all MTCs,
immunohistochemical staining for calcitonin and
carcino-embryonic antigen (CEA) is positive (Figure 1). 
Hereditary MTC is generally bilateral and multifocal,
whereas in sporadic MTC the tumour is most frequently
unilateral. In addition, in practically all patients with
hereditary MTC, C-cell hyperplasia (CCH) is present
(Figure 1) [9]. Wolfe et al. were in 1973 the first to
describe CCH as the presence of a multifocal increase
and clustering of noninvasive calcitonin-containing cells
in the absence of grossly visible tumour in two related
patients with abnormally high serum levels of stimulated
calcitonin [10]. Hereditary MTC develops stepwise via
CCH (Figure 2). In addition, CCH accompanies (and
probably precedes) a number of sporadic MTC but CCH
is frequently absent in these cases [11]. Moreover,
physiologic CCH is associated with inflammatory and
metabolic thyroid disorders as well as with
hypercalcaemia and in the general population it is present
in 20% to 30% of normal (non-cancerous) thyroids [12]. 
Metastases to regional lymph nodes happen early
in the course of disease and have frequently already
occurred at the time of diagnosis. The central
Fig. 1. [A] Microscopic view of normal thyroid tissue with hyperplastic C-cells (arrows) dispersed between the follicles. C-cell hyperplasia
(CCH) was defined as clusters of intrafollicular atypical C-cells (more than 50 per “low-power field” at 100x magnification) that lead to
partial or complete obliteration of the follicular space. [B] C-cells are positive for immunohistochemical staining for calcitonin (dark areas).
[C] Microscopic view of medullary thyroid cancer (MTC). Malignant C-cells have broken through the basement membrane and invaded
the interstitium, which has led to stromal fibrosis (arrows). MTC lesions are composed of solid nests of epithelial cells with poorly defined
cell borders. [D] Occasionally there is deposition of intensely eosinophilic material, amyloid, which can be stained with Congo-red (arrow).
Amyloid is derived from calcitonin
A B
C D
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(paratracheal) lymph nodes are most often involved
followed by the ipsilateral, contralateral (jugular) and
mediastinal lymph nodes [13]. Distant metastases
develop variably in the course of MTC, usually to the
liver, lungs, and bone [3, 14].
Secretion products
MTC synthesizes and secretes a wide range of
substances, the most abundant being calcitonin [15].
Calcitonin is a small 32 amino acid polypeptide
hormone and the main biochemical marker used for
detection and postoperative management of patients
with MTC [16, 17]. Elevated serum calcitonin levels are
found in patients with MTC, CCH or, rarely, in patients
without any C-cell abnormalities. Patients with renal
insufficiency, Hashimoto’s thyroiditis and (metastatic)
carcinoids can also have elevated serum calcitonin levels.
In neonates, serum calcitonin levels are high but these
levels decline to normal by one year of age [4, 18].
Generally, basal serum calcitonin roughly correlates with
tumour burden, although there are exceptions, especially
in patients with extensively metastasized MTC.
Furthermore, in small tumours and CCH serum calcitonin
levels may be normal. Calcitonin can then be stimulated
by pentagastrin, calcium or omeprazole but pentagastrin
is the provocative agent of choice [18-20].
Another tumour marker for MTC is CEA, which is
mainly produced by neoplastic C-cells but also found
in normal C-cells. Measurement of serum CEA levels
is useful in the follow-up of MTC since rapidly
increasing CEA levels can indicate dedifferentiation of
the tumour [21, 22]. 
MTCs not only secrete calcitonin and CEA. Other
secretion products include serotonin (causing carcinoid
syndrome), prostaglandins, corticotropin releasing
factor, adrenocorticotropic hormone (causing Cushing’s
syndrome), histaminase, and somatostatin (which may
cause paraneoplastic clinical syndromes). Furthermore,
MTC is known to produce several gastrointestinal
hormones and neuroendocrine peptides, including
calcitonin gene related peptide, chromogranin A,
vasoactive intestinal peptide, and ghrelin [15]. 
There is increasing evidence for a subgroup of
MTCs that do not secrete calcitonin, CEA or both,
making tumour follow-up difficult [23-25]. Although
calcitonin (and CEA) is not a perfect tumour marker,
none of the other secretion products is comparable to
calcitonin in terms of sensitivity and specificity. 
Clinical presentation
Most patients with sporadic MTC present in the
fourth or fifth decade of life with a painless thyroid
nodule often accompanied by cervical
lymphadenopathy (Figure 3). Sometimes patients have
pain in the neck, dysphagia, respiratory difficulties,
hoarseness or symptoms of ectopic hormone
production such as diarrhoea, flushes or Cushing’s
syndrome [15]. Patients with hereditary MTC may also
present with a neck mass. Additionally, patients with
MEN 2 or FMTC may have symptoms characteristic
of pheochromocytoma.
Fine-needle aspiration cytology (FNAC) can reveal
the diagnosis prior to surgery, especially when
immunohistochemical staining for calcitonin is
performed, but FNAC may be inconclusive or only
diagnose malignancy. Measurement of serum calcitonin
may then be a complementary approach to make the
final diagnosis [26]. However, if basal calcitonin is
elevated, a pentagastrin stimulation test should always
follow to confirm that the source of elevated calcitonin
concentrations is indeed MTC. 
Sporadic and hereditary medullary thyroid
cancer
As mentioned earlier, MTC may be sporadic or
hereditary. Sporadic MTC is the most common form of
MTC, accounting for approximately 75% of all cases
at initial presentation. The remaining 25% comprise
hereditary MTC including MEN 2A (most common),
MEN 2B, and FMTC (the least common) (Table 1).
In 1962 Sipple was the first to describe the
association of MTC with pheochromocytoma and
hyperparathyroidism [27]. In 1966 Williams and
Pollock described the association between oral mucosal
and eyelid neuromas, MTC, pheochromocytoma, and
ganglioneuromatosis of the gastro-intestinal tract in a
father and a daughter [28]. 
Two years later, in 1968, Steiner et al. introduced
the term “multiple endocrine neoplasia” to describe
different combinations of endocrine tumours. They
designated the combination MTC, pheochromocytoma
and parathyroid adenoma as MEN 2 [29]. Sizemore
thyroid follicle C-cell C-cell
hyperplasia
cancer
Fig. 2. Development of medullary thyroid cancer (MTC) from a
normal C-cell via C-cell hyperplasia (CCH) to MTC
Hereditary Cancer in Clinical Practice 2006; 4(3)118
et al. concluded in 1973 that the MEN 2 category
included two distinct groups of patients with MTC and
pheochromocytoma: patients with hyperparathyroidism
and a normal physical appearance and patients
without parathyroid disease but with marfanoid habitus,
mucosal neuromas, and alimentary abnormalities. They
suggested the title “MEN type 2B” for the group without
parathyroid disease [30]. Subsequently, in 1975,
Chong et al. proposed that the combination of MTC,
pheochromocytoma, and parathyroid disease in
patients with a normal appearance be referred to as
MEN type 2A [31].
Genetic background
In 1993, characteristic germline mutations of the
RET gene on chromosome 10 were shown to be
responsible for the inherited forms of MTC [5-7]. RET
contains 21 exons and encodes the transmembrane
tyrosine kinase receptor RET (Figure 4). In patients with
a family history of MEN 2 or FMTC, it is now possible
to determine the risk of MTC by genetic screening. As
it is a dominantly inherited disease, about 50% of
family members do not carry a germline RET mutation.
Family members with a RET mutation have a 100% risk
Jan Willem de Groot, Thera P. Links, Robert M.W. Hofstra, John T.M. Plukker
Table 1. Clinical expression of the variants of hereditary MTC associated syndromes
FMTC MEN 2A MEN 2B
medullary thyroid cancer 100% 100% 100%
C-cell hyperplasia 100% 100% 100%
Pheochromocytoma 0% 10% to 60% 50%
Hyperparathyroidism 0% 10% to 25% 0%
Marfanoid habitus 0% 0% 100%
Intestinal ganglioneuromatosis 0% 0% 60% to 90%
Mucosal neuromas 0% 0% 70% to 100%
thick corneal nerves 0% Rare 60% to 90%
FMTC, familial medullary thyroid cancer; MEN 2A/2B, multiple endocrine neoplasia type 2A/2B
Fig. 3. Magnetic Resonance Imaging (MRI) of the neck of a 51-year-old woman with a germline V804L RET mutation demonstrating a
thyroid nodule (arrow on the right) and cervical lymphadenopathy (arrow on the left)
A B
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of developing MTC, whereas family members that do
not carry a RET mutation have a risk that is similar to
the general population. In patients with apparently
sporadic MTC germline RET mutations are found in 4%
to 10% of cases [4]. In up to 30% of patients with
sporadic MTC, somatic mutations (occurring only in
the tumour) in RET are present [32].
Before 1993, screening for hereditary MTC
consisted primarily of family history followed by testing
for elevated basal and pentagastrin stimulated serum
calcitonin levels to identify asymptomatic gene carriers.
This method requires frequent screening and the main
disadvantage is that it is impossible to distinguish
between asymptomatic gene carriers and family
members that will never develop MTC. Furthermore,
there is a risk of false-positive test results leading to
unnecessary thyroidectomy and it is not possible to
distinguish between CCH and invasive cancer [33, 34]. 
After 1993, DNA testing was used to classify MTC
as being of the inherited type and to identify relatives of
patients with a mutated RET gene prior to the
development of clinical and biochemical signs of the
disease. Using DNA analysis, a reliable estimation of
the risk of MTC can be given since all patients with a
germline RET mutation will eventually develop MTC.
Identification of the type of RET mutation has led to the
implementation of early prophylactic thyroidectomy [35]. 
Treatment
Management of MTC is primarily surgical. MTC
does not respond to standard chemotherapeutic
regimens and external beam radiotherapy has a limited
effect in selected groups of patients. Moreover,
treatment with radioactive iodine is of no significant
value since C-cells do not take up iodine [15, 32]. 
Due to the high likelihood of a familial component
and the risks of other tumours associated with MEN 2,
all patients with MTC should be genetically screened
for RET mutations. Furthermore, a systematic work-up
for pheochromocytoma including 24-hour urine
collection for catecholamines and metabolites should
be performed. Pheochromocytomas need to be treated
before undertaking surgery for MTC in order to avoid
a potentially lethal intraoperative hypertensive crisis.
Patients with possible MEN 2A should also have serum
calcium and possible parathormone levels evaluated
to rule out hyperparathyroidism. 
In recent years great progress has been made
regarding genotype-phenotype correlations in MEN 2
and FMTC. Based on the biological behaviour of MTC
observed in patients with a germline RET mutation, a
codon-specific estimation of the risk for MTC can be
made (Table 2). Figure 5 shows an overview of the
known germline mutations of RET. In MEN 2A the most
frequent mutations are found in exons 10 and 11 on
codons 609, 611, 618, 620, 630 and 634. Mutations
in exons 13, 14, and 15 on codons 768, 790, 791,
804 and 891 and mutations in codon 666 on exon
11 are very rare. In FMTC mutations are found in the
same codons as in MEN 2A except for FMTC-specific
mutations in codons 533 (exon 8), 600, 603, 606,






RET 9 (1.072 aa)
RET 43 (1.106 aa)
RET 51 (1.114 aa)
cell membrane
Fig. 4. Copyright 2006, The Endocrine Society. Schematic
representation of the RET tyrosine kinase. The extracellular region
comprises four cadherin domains and a cysteine rich domain. A
single transmembrane region spans the cell membrane, and the two
tyrosine kinase domains (TK1 and TK2) are located in the
intracellular region. There are three isoforms of RET (RET9, RET43,
RET 51) which are indicated. aa, Amino acids. [Adapted from De
Groot et al. [35]]
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MEN 2A MEN 2B +HSCR +CLA
Fig. 5. Copyright 2006, The Endocrine Society. Overview of the known germline missense mutations in the RET gene and their associated
human diseases. The structure of the RET mRNA and the RET protein are depicted schematically. The mutations responsible for the diverse
inherited cancer syndromes and the location of the mutations relative to the exons and the functional domains are shown. The most common
mutations that are found in about 95% of MEN 2A and FMTC cases are depicted in bold, and MEN 2B mutations are depicted in italics.
CLA, Cutaneous lichen amyloidosis. [Adapted from De Groot et al. [35]]
divided among the different exons. In MEN 2B
mutations are almost always found in exon 16 (codons
883, 918) [35]. In the Netherlands exons 10, 11, 13,
14, 15 and 16 are routinely screened for germline
mutations when a form of hereditary MTC is suspected.
In case of a strong suspicion of inherited MTC and the
absence of mutations in exons 10, 11, 13, 14, 15 and
16, screening of exon 8 may be considered. 
In the University Medical Center of Groningen, 
21 children with MEN 2A underwent prophylactic
thyroidectomy. The clinical characteristics are summarized
in Table 3. MTC was already present at the age of three
years, and in the literature MEN 2A-associated MTC is
described at the age of one year [36]. Therefore, early
surgical intervention in patients with an RET mutation is
warranted. 
Carriers of a germline RET mutation sooner or later
will develop MTC and surgery is the only curatively
intended treatment of this form of cancer. The turning
point of progression from CCH into invasive MTC is as
yet unknown. When surgery takes place at a young age
(at the age of three or four years) the risk of invasive MTC
is low and the extent of surgery can be minimal (only a
total thyroidectomy) with low risk of hypoparathyroidism
or paralysis of the recurrent laryngeal nerve. 
In our patients, 20 of 21 patients had C-cell disease
and in five of seven patients (71%) younger than five
years old (the youngest being three years old) MTC was
already present. Based on the youngest age at which
MTC was already present a total thyroidectomy seems
warranted before the age of two in carriers of RET
mutations in codons 630 and 634 (Table 2). However,
it should be noted that all patients with such a mutation
who have been operated on around the age of 4 years
were biochemically cured [35]. 
The prognosis of MTC attenuates with the presence
of lymph node metastases [36]. Therefore it is crucial
that prophylactic thyroidectomy is performed before the
Hereditary Cancer in Clinical Practice 2006; 4(3)122
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Table 3. Occurrence of MTC related to patient characteristics and type of RET gene mutation in children who underwent prophylactic thyroidectomy
for multiple endocrine neoplasia type 2A
Patient/ Year Sex Age Type of RET Calcitonin (ng/L) Lymph node Histology
family of surgery (year) mutation Basal/Stimulateda dissection (initially)
1/A 1976 M 17 M918Tb – central and multifocal MTC; positive lymph nodes
unilateral  (level II-V)
2/B 1998 F 18 C634G 2000/31600 central multifocal MTC; positive lymph nodes
3/C 1999 M 14 C634R 151/1200 central multifocal MTC; positive lymph nodes
4/D 1977 F 18 C634R – central multifocal MTC
5/D 1978 M 17 C634R 489/– central multifocal MTC
6/E 1995 F 5 C634R 61/198 central exploration multifocal MTC
7/C 1999 F 12 C634R 12/125 central exploration multifocal MTC
8/F 2000 F 5 C634Y 34/– central exploration multifocal MTC
9/B 2004 F 3 C634G 72/188 central multifocal MTC
10/G 2005 F 11 C634R 13/– central multifocal MTC
11/F 1995 F 11 C634Y 24/122 central exploration unifocal MTC
12/H 1999 M 4 C634R 5/384 – unifocal MTC
13/I 2000 F 6 C620R 15/– central unifocal MTC
14/J 1995 F 4 C634W/R635G 18/447 central unifoclal MTC
15/J 1990 F 14 C634W/R635G 632/– – CCH
16/K 1990 F 7 C634R 63/– central exploration CCH
17/K 1990 M 10 C634R 92/– central CCH
18/F 1995 M 11 C634Y 79/177 central exploration CCH
19/F 2004 F 1 C634Y 48/– central CCH
20/L 2005 M 16 V804L 13/32 central CCH
21/I 1997 F 5 C620R 13/– – no C-cell disease
abefore 2001 the reference value was <50 ng/L, after 2001 the reference value was <12 ng/L;
bpatient with multiple endocrine neoplasia type 2B;
RET – rearranged during transfection; F – female; CCH – C-cel hyperplasia; M – male; MTC – medullary thyroid carcinoma
development of MTC and possible node metastases. In
adults with MTC, lymph node metastases are already
present in about 50% of cases, even in tumours smaller
than 1 cm. However, in children without symptoms in
whom a RET mutation is detected via genetic screening
lymph node metastases infrequently occur [36, 37]. 
There is still no ‘gold standard’ concerning the extent
of lymph node dissection that should be performed in
addition to total thyroidectomy [38]. Furthermore, it is
controversial from what age to perform a lymph node
dissection. The results of this study confirm the data of
others in which lymph node metastases in patients with
MEN 2A and FMTC are almost always found after the
age of 10 years. Patients with an RET mutation in codon
630 or 634 hardly ever have metastases before the age
of 10 years and patients with mutations in codons 609,
611, 618, 620, 768, 790, 791, 804 and 891 rarely
have metastases before the age of 20 years [36, 37].
Until the age of 10 years, a total thyroidectomy should
be sufficient in patients with MEN 2A or FMTC. However,
several patients younger than 10 years old have been
described with lymph node metastases. The risk of
invasive MTC and possible nodal metastases is present
in the case of elevated serum calcitonin levels as recently
illustrated by Van Santen and colleagues [39]. For that
reason, a central compartment dissection in addition to
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total thyroidectomy to remove possible occult lymph
node metastases is indicated when basal or stimulated
serum calcitonin levels are elevated (Table 2) [35, 36]. 
Careful preservation of recurrent nerves and
parathyroid glands may be difficult in very young
children. The risk of injuring recurrent nerves at risk after
thyroid surgery in the literature varies between 0% and
4% and symptomatic hypoparathyroidism with calcium
supplementation occurs in 0% to 21% [40-56]. The
incidence of complications strongly depends on the
experience of the surgeon [44, 50, 57]. Hence, thyroid
surgery in children should be performed in a referral
centre with large experience in this form of surgery. Total
thyroidectomy and central compartment dissection is
then relatively safe. Even with meticulous dissection
however, the blood supply to the parathyroid glands may
be impaired. In these circumstances autotransplantation
after microscopic verification may reduce the incidence
of hypoparathyroidism [40, 41, 47].
The risk of bilateral lymph node metastases is high
in patients who present with a palpable thyroid nodule
or nodal metastases (the majority of patients with
sporadic MTC). In these cases, elective bilateral
selective neck dissection of level II to V is recommended
in addition to total thyroidectomy and central
compartment dissection [36]. In children with MEN 2B
the risk of node metastases is very high and total
thyroidectomy with central compartment dissection is
justified in the first year of life [36, 37, 48]. 
Prognosis and follow-up
The prognosis of patients with MTC varies
considerably: some patients survive several decades with
persistent MTC, whereas others die within months of initial
presentation [3, 14]. Five and 10-year overall survival
rates in patients with MTC without the presence of distant
metastases at initial diagnosis range from 70% to 90%
and 60% to 80%, respectively [14, 58-60]. When
matched for age and extent of disease, no differences in
survival were seen in patients with either hereditary or
sporadic MTC but MEN 2B-associated MTC has been
reported to be more aggressive than MTC associated
with MEN 2A or FMTC [3, 59]. In multivariate analysis,
only the patients’ stage of disease at diagnosis is a
significantly independent indicator of survival [60]. 
Patients with normal basal and stimulated serum
calcitonin levels are likely to be cured. However, in
approximately 5% of these patients, serum calcitonin
levels can rise again during follow-up [4]. Currently,
the only treatment option in patients with detectable
serum calcitonin levels after initial treatment is re-
operation. Yet re-operation can only be with curative
intent in the absence of distant metastases when
residual or recurrent MTC is confined to the neck. In
patients with postoperative hypercalcitoninemia, the
source of calcitonin production is hard to identify with
conventional medical imaging and distant metastases
cannot be reliably ruled out [61]. When distant
metastases are present, therapeutic options are limited.
Conclusion
MTC can occur in a sporadic form and as part of
the hereditary cancer syndromes MEN 2A/B or FMTC.
In carriers of MEN 2B-associated RET mutations,
prophylactic thyroidectomy is indicated before the first
year of life. In case of MEN 2A-associated germline RET
mutations with a high-risk profile, total thyroidectomy is
warranted before the age of 2 years and certainly before
the age of 4 years. At that age the risk of invasive MTC
and metastases is acceptably low. Depending on the
type of RET mutation, thyroidectomy can be performed
at an older age in patients with a lower risk profile. In
case of elevated basal or stimulated serum calcitonin
preventive surgery including total thyroidectomy and
central compartment dissection should in any case be
performed at any age. When MTC presents as a
palpable tumour, total thyroidectomy should be
combined with extensive lymph node dissection of levels
II-V on both sides and level VI to prevent locoregional
recurrences. This kind of surgery can be performed
relatively safely by well-experienced surgeons.
References
1. Hazard JB, Hawk WA and Crile Jr G. Medullary (solid)
carcinoma of the thyroid; a clinicopathologic entity. J Clin
Endocrinol Metab 1959; 19: 152-161.
2. Hundahl SA, Fleming ID, Fremgen AM and Menck HR. A
National Cancer Data Base report on 53,856 cases of thyroid
carcinoma treated in the U.S., 1985-1995 [see comments].
Cancer 1998; 83: 2638-2648.
3. Kebebew E, Ituarte PH, Siperstein AE, Duh QY and Clark OH.
Medullary thyroid carcinoma: clinical characteristics, treatment,
prognostic factors, and a comparison of staging systems. Cancer
2000; 88: 1139-1148.
4. Leboulleux S, Baudin E, Travagli JP and Schlumberger M.
Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004; 61:
299-310.
5. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner
E, Love DR, Mole SE, Moore JK, Papi L, et al. Germ-line
mutations of the RET proto-oncogene in multiple endocrine
neoplasia type 2A. Nature 1993; 363: 458-460.
6. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore
TC, Howe JR, Moley JF, Goodfellow P and Wells SA Jr. Mutations
in the RET proto-oncogene are associated with MEN 2A and
FMTC. Hum Mol Genet 1993; 2: 851-856.
7. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T,
Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, et al.
A mutation in the RET proto-oncogene associated with multiple
Hereditary Cancer in Clinical Practice 2006; 4(3)124
endocrine neoplasia type 2B and sporadic medullary thyroid
carcinoma. Nature 1994; 367: 375-376.
8. Khurana R, Agarwal A, Bajpai VK, Verma N, Sharma AK, Gupta
RP and Madhusudan KP. Unraveling the amyloid associated with
human medullary thyroid carcinoma. Endocrinology 2004; 145:
5465-5470.
9. Livolsi VA. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab
1997; 82: 39-41.
10. Wolfe HJ, Melvin KE, Cervi-Skinner SJ, Saadi AA, Juliar JF,
Jackson CE and Tashjian AH Jr. C-cell hyperplasia preceding
medullary thyroid carcinoma. N Engl J Med 1973; 289: 437-
441.
11. Guyetant S, Josselin N, Savagner F, Rohmer V, Michalak S and
Saint-Andre JP. C-cell hyperplasia and medullary thyroid
carcinoma: clinicopathological and genetic correlations in 66
consecutive patients. Mod Pathol 2003; 16: 756-763.
12. Guyetant S, Rousselet MC, Durigon M, Chappard D, Franc B,
Guerin O and Saint-Andre JP. Sex-related C cell hyperplasia in
the normal human thyroid: a quantitative autopsy study. J Clin
Endocrinol Metab 1997; 82: 42-47.
13. Quayle FJ and Moley JF. Medullary thyroid carcinoma: including
MEN 2A and MEN 2B syndromes. J Surg Oncol 2005; 89:
122-129.
14. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey
RC and Samaan NA. Medullary carcinoma of the thyroid. A
study of the clinical features and prognostic factors in 161
patients. Medicine (Baltimore) 1984; 63: 319-342.
15. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G and
Angeli A. Treatment of medullary thyroid carcinoma: an update.
Endocr Relat Cancer 2001; 8: 135-147.
16. Tashjian AH, Jr. and Melvin EW. Medullary carcinoma of the
thyroid gland. Studies of thyrocalcitonin in plasma and tumour
extracts. N Engl J Med 1968; 279: 279-283.
17. Goltzman D, Potts JT, Jr., Ridgway RC and Maloof F. Calcitonin
as a tumour marker. Use of the radioimmunoassay for calcitonin
in the postoperative evaluation of patients with medullary thyroid
carcinoma. N Engl J Med 1974; 290: 1035-1039.
18. Karanikas G, Moameni A, Poetzi C, Zettinig G, Kaserer K,
Bieglmayer C, Niederle B, Dudczak R and Pirich C. Frequency
and relevance of elevated calcitonin levels in patients with
neoplastic and nonneoplastic thyroid disease and in healthy
subjects. J Clin Endocrinol Metab 2004; 89: 515-519.
19. Gharib H, Kao PC and Heath H, III. Determination of silica-
purified plasma calcitonin for the detection and management
of medullary thyroid carcinoma: comparison of two provocative
tests. Mayo Clin Proc 1987; 62: 373-378.
20. Vitale G, Ciccarelli A, Caraglia M, Galderisi M, Rossi R, Del
Prete S, Abbruzzese A and Lupoli G. Comparison of two
provocative tests for calcitonin in medullary thyroid carcinoma:
omeprazole vs pentagastrin. Clin Chem 2002; 48: 1505-1510.
21. Busnardo B, Girelli ME, Simioni N, Nacamulli D and Busetto E.
Nonparallel patterns of calcitonin and carcinoembryonic antigen
levels in the follow-up of medullary thyroid carcinoma. Cancer
1984; 53: 278-285.
22. Mendelsohn G, Wells SA, Jr. and Baylin SB. Relationship of tissue
carcinoembryonic antigen and calcitonin to tumour virulence
in medullary thyroid carcinoma. An immunohistochemical study
in early, localized, and virulent disseminated stages of disease.
Cancer 1984; 54: 657-662.
23. Sobol RE, Memoli V and Deftos LJ. Hormone-negative,
chromogranin A-positive endocrine tumours. N Engl J Med
1989; 320: 444-447.
24. Redding AH, Levine SN and Fowler MR. Normal preoperative
calcitonin levels do not always exclude medullary thyroid
carcinoma in patients with large palpable thyroid masses.
Thyroid 2000; 10: 919-922.
25. Bockhorn M, Frilling A, Rewerk S, Liedke M, Dirsch O, Schmid
KW and Broelsch CE. Lack of elevated serum carcinoembryonic
antigen and calcitonin in medullary thyroid carcinoma. Thyroid
2004; 14: 468-470.
26. Bugalho MJ, Santos JR and Sobrinho L. Preoperative diagnosis
of medullary thyroid carcinoma: fine needle aspiration cytology
as compared with serum calcitonin measurement. J Surg Oncol
2005; 91: 56-60.
27. Sipple JH. The association of pheochromocytoma with
carcinoma of the thyroid gland. Am J Med 1961; 31: 163-166.
28. Williams ED and Pollock DJ. Multiple mucosal neuromata with
endocrine tumours: a syndrome allied to von Recklinghausen’s
disease. J Pathol Bacteriol 1966; 91: 71-80.
29. Steiner AL, Goodman AD and Powers SR. Study of a kindred
with pheochromocytoma, medullary thyroid carcinoma,
hyperparathyroidism and Cushing’s disease: multiple endocrine
neoplasia, type 2. Medicine (Baltimore) 1968; 47: 371-409.
30. Carney JA. Familial multiple endocrine neoplasia: the first 100
years. Am J Surg Pathol 2005; 29: 254-274.
31. Chong GC, Beahrs OH, Sizemore GW and Woolner LH.
Medullary carcinoma of the thyroid gland. Cancer 1975; 35:
695-704.
32. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A,
Tagliaferri P and Lupoli G. Current approaches and perspectives
in the therapy of medullary thyroid carcinoma. Cancer 2001;
91: 1797-1808.
33. Telander RL, Zimmerman D, van Heerden JA and Sizemore GW.
Results of early thyroidectomy for medullary thyroid carcinoma
in children with multiple endocrine neoplasia type 2. J Pediatr
Surg 1986; 21: 1190-1194.
34. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham
G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends
MJ, et al. Clinical screening as compared with DNA analysis in
families with multiple endocrine neoplasia type 2A. N Engl J
Med 1994; 331: 828-835.
35. de Groot JW, Links TP, Plukker JT, Lips CJ and Hofstra RM. RET
as a diagnostic and therapeutic target in sporadic and hereditary
endocrine tumours. Endocr Rev 2006; 27: 535-560.
36. Machens A, Ukkat J, Brauckhoff M, Gimm O and Dralle H.
Advances in the management of hereditary medullary thyroid
cancer. J Intern Med 2005; 257: 50-59.
37. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van
Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-
Devolx B, Dralle H; European Multiple Endocrine Neoplasia
(EUROMEN) Study Group. Early malignant progression of
hereditary medullary thyroid cancer. N Engl J Med 2003; 349:
1517-1525.
38. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi
C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ,
Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid
B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P,
Tonelli F, Wells SA Jr and Marx SJ. Guidelines for diagnosis and
therapy of MEN type 1 and type 2. J Clin Endocrinol Metab
2001; 86: 5658-5671.
39. van Santen HM, Aronson DC, van Trotsenburg AS, ten Kate FJ,
van de Wetering MD, Wiersinga WM, de Vijlder JJ and Vulsma
T. Disseminated Medullary Thyroid Carcinoma Despite Early
Thyroid Surgery in the Multiple Endocrine Neoplasia-2A
Syndrome. Thyroid 2005; 15: 485-488.
40. Decker RA, Geiger JD, Cox CE, Mackovjak M, Sarkar M and
Peacock ML. Prophylactic surgery for multiple endocrine
neoplasia type IIa after genetic diagnosis: is parathyroid
transplantation indicated? World J Surg 1996; 20: 814-820.
Jan Willem de Groot, Thera P. Links, Robert M.W. Hofstra, John T.M. Plukker
Hereditary Cancer in Clinical Practice 2006; 4(3) 125
Medullary Thyroid Cancer
41. Skinner MA, Norton JA, Moley JF, DeBenedetti MK and Wells
SA, Jr. Heterotopic autotransplantation of parathyroid tissue in
children undergoing total thyroidectomy. J Pediatr Surg 1997;
32: 510-513.
42. Frank-Raue K, Hoppner W, Buhr H, Herfarth C and Raue F.
Results and follow-up in eleven MEN 2A gene carriers after
prophylactic thyroidectomy. Exp Clin Endocrinol Diabetes 1997;
105 Suppl 4: 76-78.
43. Hotz HG, Runkel NS, Frank-Raue K, Raue F and Buhr HJ.
Prophylactic thyroidectomy in MEN IIA: does the calcitonin level
correlate with tumour spread? Langenbecks Arch Surg 1998;
383: 170-173.
44. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle
B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM,
Spelsberg F, Heiss A, Hinze R and Hoppner W. Prophylactic
thyroidectomy in 75 children and adolescents with hereditary
medullary thyroid carcinoma: German and Austrian experience.
World J Surg 1998; 22: 744-750.
45. Wells SA, Jr. and Skinner MA. Prophylactic thyroidectomy, based
on direct genetic testing, in patients at risk for the multiple
endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol
Diabetes 1998; 106: 29-34.
46. Lallier M, St-Vil D, Giroux M, Huot C, Gaboury L, Oligny L and
Desjardins JG. Prophylactic thyroidectomy for medullary thyroid
carcinoma in gene carriers of MEN2 syndrome. J Pediatr Surg
1998; 33: 846-848.
47. Arts CH, Bax NM, Jansen M, Lips CJ, Vroom TM and van
Vroonhoven TJ. Prophylactic total thyroidectomy in childhood
for multiple endocrine neoplasia type 2A: preliminary results.
Ned Tijdschr Geneeskd 1999; 143: 98-104.
48. van Heurn LW, Schaap C, Sie G, Haagen AA, Gerver WJ, Freling
G, van Amstel HK and Heineman E. Predictive DNA testing for
multiple endocrine neoplasia 2: a therapeutic challenge of
prophylactic thyroidectomy in very young children. J Pediatr Surg
1999; 34: 568-571.
49. Iler MA, King DR, Ginn-Pease ME, O’Dorisio TM and Sotos JF.
Multiple endocrine neoplasia type 2A: a 25-year review. J Pediatr
Surg 1999; 34: 92-96.
50. Niccoli-Sire P, Murat A, Baudin E, Henry JF, Proye C, Bigorgne
JC, Bstandig B, Modigliani E, Morange S, Schlumberger M and
Conte-Devolx B. Early or prophylactic thyroidectomy in MEN
2/FMTC gene carriers: results in 71 thyroidectomized patients.
The French Calcitonin Tumours Study Group (GETC). Eur J
Endocrinol 1999; 141: 468-474.
51. Ukkat J, Lorenz K, Hinze R, Thomusch O and Dralle H.
Importance of early screening and prophylactic thyroidectomy
in asymptomatic nonindex RET germline carriers. World J Surg
2001; 25: 713-717.
52. Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M,
Ring A, Perinetti H, Elsner B, Iorcansky S and Barontini M. Very
early detection of RET proto-oncogene mutation is crucial for
preventive thyroidectomy in multiple endocrine neoplasia type
2 children: presence of C-cell malignant disease in asymptomatic
carriers. Cancer 2002; 94: 323-330.
53. Rodriguez GJ, Balsalobre MD, Pomares F, Torregrosa NM, Rios
A, Carbonell P, Glower G, Sola J, Tebar J and Parrilla P.
Prophylactic thyroidectomy in MEN 2A syndrome: experience in
a single center. J Am Coll Surg 2002; 195: 159-166.
54. Brauckhoff M, Gimm O, Weiss CL, Ukkat J, Sekulla C,
Brauckhoff K, Thanh PN and Dralle H. Multiple endocrine
neoplasia 2B syndrome due to codon 918 mutation: clinical
manifestation and course in early and late onset disease. World
J Surg 2004; 28: 1305-1311.
55. Kahraman T, de Groot JW, Rouwe C, Hofstra RM, Links TP,
Sijmons RH and Plukker JT. Acceptable age for prophylactic
surgery in children with multiple endocrine neoplasia type 2a.
Eur J Surg Oncol 2003; 29: 331-335.
56. de Groot JW, Links TP, Rouwe CW, van der Wal JE, Hofstra RM
and Plukker JT. Prophylactic thyroidectomy in children who are
carriers of a multiple endocrine neoplasia type 2 mutation:
description of 20 cases and recommendations based on the
literature. Ned Tijdschr Geneeskd 2006; 150: 311-318.
57. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA and
Udelsman R. The importance of surgeon experience for clinical
and economic outcomes from thyroidectomy. Ann Surg 1998;
228: 320-330.
58. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B,
Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc
L, Corcuff B and Guilhem I. Prognostic factors for survival and
for biochemical cure in medullary thyroid carcinoma: results in
899 patients. The GETC Study Group. Groupe d’etude des
tumeurs a calcitonine. Clin Endocrinol (Oxf) 1998; 48: 265-
273.
59. Hyer SL, Vini L, A’Hern R and Harmer C. Medullary thyroid
cancer: multivariate analysis of prognostic factors influencing
survival. Eur J Surg Oncol 2000; 26: 686-690.
60. de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter
WJ and Links TP. Determinants of life expectancy in medullary
thyroid cancer: Age does not matter. Clin Endocrinol (Oxf) 2006
(in press).
61. de Groot JW, Links TP, Jager PL, Kahraman T and Plukker JT.
Impact of 18F-fluoro-2-deoxy-D-glucose positron emission
tomography (FDG-PET) in patients with biochemical evidence
of recurrent or residual medullary thyroid cancer. Ann Surg Oncol
2004; 11: 786-794.
